Reduced-Dose Tralokinumab Maintains Symptom Control for Up to 1 Year in Atopic Dermatitis

Adults with moderate-to-severe atopic dermatitis (AD) who achieved initial disease control with tralokinumab maintained improvements in symptoms and quality of life for up to 1 year following reduced dosing, according to a South Beach Symposium poster from April Armstrong, MD, MPH, et al.

The analysis evaluated patients who achieved clear or almost clear skin after induction therapy and were subsequently re-randomized to less frequent tralokinumab dosing. Outcomes included itch, sleep disturbance, and Dermatology Life Quality Index scores.

Across assessed endpoints, symptom control was sustained through 52 weeks, with comparable outcomes observed between standard and reduced dosing schedules. Improvements in itch and sleep were maintained without evidence of clinically meaningful loss of efficacy.

The authors noted that reduced dosing may offer flexibility for long-term disease management in selected patients who respond well to initial therapy. Safety findings were consistent with the known profile of IL-13 inhibition.

“Tralokinumab provided sustained improvements in itch, sleep, and quality of life in patients with moderate-to-severe AD who had achieved clear or almost clear skin,” the investigators concluded.